Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
Marina SerranoNerea Muñoz-UncetaLucía Andrea AlonsoAinara AzuetaJosé Luis Gutiérrez BañosLaura FerreiraMario DomínguezAlbero Torres ZuritaRoberto BallesteroDiego CachoMarta López-BreaMarta SoteloFélix Campos-JuanateyEnrique Ramos BarselóIgnacio DuranPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Neoadjuvant chemotherapy with 4 cycles of dd-MVAC is an effective regimen with high rates of pathological complete responses and down-staging along with an acceptable toxicity profile. DD-MVAC should be considered as an alternative to cisplatin and gemcitabine in patients with good clinical performance status.